Jingxin Pharmaceutical Announcement: Subsidiary Shaoxing Jingxin Pharmaceutical Co., Ltd. received the Certificate of Suitability to the European Pharmacopoeia (CEP Certificate) for the active pharmaceutical ingredient Enrofloxacin issued by the European Medicines Agency. Enrofloxacin belongs to the quinolone class of synthetic antibacterial agents and is mainly used to treat infectious diseases in animals.
京新药业：子公司恩诺沙星原料药获得欧洲CEP证书
Zhejiang Jingxin Pharmaceutical: Subsidiary Enrofloxacin Active Pharmaceutical Ingredient Obtained Europe CEP Certificate.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.